Zobrazeno 1 - 10
of 66
pro vyhledávání: '"RC254-282"'
Autor:
Paul Frankel, Don J. Diamond, Felix Wussow, Hanne Leth Andersen, Katelyn Faircloth, Yuriy Shostak, Veronica Karpinski, Mark G. Lewis, Angelina Iniguez, Vu H. Nguyen, Jenny Nguyen, Flavia Chiuppesi, Mindy Kha, Heidi Contreras, Ankur Sharma, Teodora Kaltcheva, Joy Martinez, Daisy Johnson, Swagata Kar, Qiao Zhou, Yoonsuh Park
Publikováno v:
npj Vaccines, Vol 7, Iss 1, Pp 1-14 (2022)
NPJ Vaccines
bioRxiv
NPJ Vaccines
bioRxiv
Second-generation COVID-19 vaccines could contribute to establish protective immunity against SARS-CoV-2 and its emerging variants. We developed COH04S1, a synthetic multiantigen modified vaccinia Ankara-based SARS-CoV-2 vaccine that co-expresses spi
Autor:
Ivette A Nuñez, Prabhuanand Selvaraj, Jerry P. Weir, Charles B Stauft, Cyntia Pedro, Amy M. Woerner, Clement A. Meseda, Tony T. Wang, Christopher Z. Lien
Publikováno v:
npj Vaccines, Vol 6, Iss 1, Pp 1-10 (2021)
NPJ Vaccines
NPJ Vaccines
Numerous vaccine candidates against SARS-CoV-2, the causative agent of the COVID-19 pandemic, are under development. The majority of vaccine candidates to date are designed to induce immune responses against the viral spike (S) protein, although diff
Autor:
Melissa Oomen, Julien Villaudy, Ilja Bontjer, Philip J. M. Brouwer, Roger Le Grand, Cynthia A. van der Linden, Marloes Grobben, Yme U. van der Velden, Judith A. Burger, Meliawati Poniman, Marit J. van Gils, Mitch Brinkkemper, Tom G. Caniels, Kwinten Sliepen, Rogier W. Sanders, Pauline Maisonnasse, Joey H. Bouhuijs
Publikováno v:
npj Vaccines, Vol 6, Iss 1, Pp 1-6 (2021)
npj Vaccines, 6(1):146. Nature Publishing Group
NPJ Vaccines
npj Vaccines, 6(1):146. Nature Publishing Group
NPJ Vaccines
The emergence of SARS-CoV-2 variants that are more resistant to antibody-mediated neutralization pose a new hurdle in combating the COVID-19 pandemic. Although vaccines based on the original Wuhan sequence have been shown to be effective at preventin
Unique features of a recombinant haemagglutinin influenza vaccine that influence vaccine performance
Publikováno v:
npj Vaccines, Vol 6, Iss 1, Pp 1-8 (2021)
NPJ Vaccines
NPJ Vaccines
The influenza vaccine field has been constantly evolving to improve the speed, scalability, and flexibility of manufacturing, and to improve the breadth and longevity of the protective immune response across age groups, giving rise to an array of nex
Autor:
Matt D. Johansen, Bernadette M. Saunders, Jason Low, Erica L. Stewart, Alice Grey, Rezwan Siddiquee, Joel P. Mackay, Anupriya Aggarwal, Nayan D. Bhattacharyya, Umaimainthan Palendira, Stuart Turville, Anthony D. Kelleher, Megan Steain, James A. Triccas, Carl G. Feng, Warwick J. Britton, Owen Hutchings, Angela Ferguson, Alberto Ospina Stella, Duc H. Nguyen, Philip M. Hansbro, Nicole G. Hansbro, K. Patel, Claudio Counoupas
Publikováno v:
npj Vaccines, Vol 6, Iss 1, Pp 1-10 (2021)
NPJ Vaccines
NPJ Vaccines
Global control of COVID-19 requires broadly accessible vaccines that are effective against SARS-CoV-2 variants. In this report, we exploit the immunostimulatory properties of bacille Calmette-Guérin (BCG), the existing tuberculosis vaccine, to deliv
Autor:
Ryan W.J. Steel, Shuxiong Chen, Lucas Huntimer, Benjamin Evert, Robyn McConville, Julie Healer, Justin A Boddey, Bernd H. A. Rehm
Publikováno v:
npj Vaccines, Vol 6, Iss 1, Pp 1-12 (2021)
NPJ Vaccines
NPJ Vaccines
The current Malaria RTS,S vaccine is based on virus-like particles (VLPs) comprising the NANP repetitive epitopes from the cicumsporozoite protein (CSP) of Plasmodium falciparum. This vaccine has limited efficacy, only preventing severe disease in ab
Publikováno v:
npj Vaccines, Vol 6, Iss 1, Pp 1-8 (2021)
NPJ Vaccines
NPJ Vaccines
Merkel cell carcinoma (MCC) is a rare but aggressive skin cancer with a high mortality rate, while Merkel cell polyomavirus (MCV) has been pointed as the causative agent of MCC. A better prognosis of MCC associated with a high level of antibodies aga
Autor:
Sandrine Soman, Shelly J. Krebs, Diane L. Bolton, Gregory D. Gromowski, Ines Lakhal-Naouar, Swagata Kar, Michelle Zemil, Linda L. Jagodzinski, Amy R. Henry, Robert A. Seder, Lindsay Wieczorek, Hannah Grove, Dominic Paquin-Proulx, Adrienne Winn, Daniel C. Douek, Holly R. Hack, Caitlin Kuklis, Kamil Radzyminski, Rafael De La Barrera, Matthew Gagne, Caroline E. Peterson, James F. Wood, Heather Hernandez, Alexander R. A. Anderson, Xiankun Zeng, Stasya Zarling, Wei-Hung Chen, Mark G. Lewis, Rajeshwer S. Sankhala, Prakriti Mudvari, Andrew Pekosz, Victoria R. Polonis, Maciel Porto, Mangala Rao, Paul V. Thomas, Eli Boritz, M. Gordon Joyce, Sheila A. Peel, Elham Bayat Mokhtari, Kathryn McGuckin Wuertz, Nelson L. Michael, Sharon P. Daye, Akshaya Ganesh, Agnes Hajduczki, Gary R. Matyas, Jeffrey W. Froude, Vincent Dussupt, Erica K. Barkei, Kayvon Modjarrad, Jeffrey R. Currier, Sandhya Vasan, Janice Darden, Isabella Swafford, Elizabeth J. Martinez, Mehul S. Suthar, Ming Dong
Publikováno v:
npj Vaccines, Vol 6, Iss 1, Pp 1-11 (2021)
NPJ Vaccines
NPJ Vaccines
The emergence of SARS-CoV-2 variants of concern (VOC) requires adequate coverage of vaccine protection. We evaluated whether a SARS-CoV-2 spike ferritin nanoparticle vaccine (SpFN), adjuvanted with the Army Liposomal Formulation QS21 (ALFQ), conferre
Autor:
Jost Vielmetter, Michel C. Nussenzweig, Jennifer R. Keeffe, Priyanthi N. P. Gnanapragasam, Rajeev Gautam, Michael S. Seaman, Pamela J. Bjorkman, Amelia Escolano, Malcolm A. Martin, Morgan E. Abernathy, Yu E. Lee, Harry B. Gristick
Publikováno v:
npj Vaccines, Vol 6, Iss 1, Pp 1-9 (2021)
NPJ Vaccines
NPJ Vaccines
HIV-1 vaccine design aims to develop an immunogen that elicits broadly neutralizing antibodies against a desired epitope, while eliminating responses to off-target regions of HIV-1 Env. We report characterization of Ab1245, an off-target antibody aga
Autor:
Shane Crotty, Justin T. Kos, William R. Schief, Colin Havenar-Daughton, Yana Safonova, Jeong Hyun Lee, Laura Toy, Corey T. Watson
Publikováno v:
npj Vaccines, Vol 6, Iss 1, Pp 1-12 (2021)
NPJ Vaccines
NPJ Vaccines
A successful HIV vaccine eliciting broadly neutralizing antibodies (bnAbs) must overcome the hurdle of being able to activate naive precursor B cells encoding features within their germline B cell receptors (BCR) that allow recognition of broadly neu